Literature DB >> 21720905

Association between socioeconomic status (SES) and lower urinary tract symptom (LUTS) severity among black and white men.

Jay H Fowke1, Heather Munro, Lisa B Signorello, William J Blot, David F Penson.   

Abstract

BACKGROUND: A higher prevalence of moderate or severe lower urinary tract symptoms (LUTS) has been reported among African Americans, but the separate effects of race and socioeconomic status (SES) on LUTS severity are unclear.
OBJECTIVE: We investigated the roles of education, income, marital status, and source of health insurance on LUTS reporting among black and white U.S. men.
DESIGN: A prospective cohort within the Southern Community Cohort Study MAIN MEASURES: The International Prostate Symptom Score (IPSS) was completed during follow-up by 2488 white men and 4188 black men. Multivariable linear and logistic regression methods were used to compare IPSS scores and LUTS severity by race and SES after adjusting for age, duration of follow-up, benign prostatic hyperplasia (BPH) treatment, source of recruitment, smoking status, BMI, mode of follow-up ascertainment, and prior diagnosis of hypertension, diabetes, or hypercholesterolemia. KEY
RESULTS: Overall IPSS scores and the prevalence of moderate/severe LUTS were not significantly associated with race. Instead, higher IPSS scores were significantly associated (p < 0.05) with a lower income, marital status, and source of insurance. Education was also marginally associated with IPSS scores (p = 0.06) among black men. Furthermore, moderate/severe LUTS onset was significantly associated with a household income less than $15,000/year (OR = 1.56 (1.23, 1.96)) and having private health insurance (OR = 0.79 (0.67, 0.93)).
CONCLUSIONS: Social or behavioral factors related to SES affect LUTS reporting, and suggests a potential affect on BPH diagnosis.

Entities:  

Mesh:

Year:  2011        PMID: 21720905      PMCID: PMC3208454          DOI: 10.1007/s11606-011-1776-8

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  26 in total

1.  The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association.

Authors:  M J Barry; F J Fowler; M P O'Leary; R C Bruskewitz; H L Holtgrewe; W K Mebust; A T Cockett
Journal:  J Urol       Date:  1992-11       Impact factor: 7.450

2.  Genetic variation of 3 beta-hydroxysteroid dehydrogenase type II in three racial/ethnic groups: implications for prostate cancer risk.

Authors:  S A Devgan; B E Henderson; M C Yu; C Y Shi; M C Pike; R K Ross; J K Reichardt
Journal:  Prostate       Date:  1997-09-15       Impact factor: 4.104

3.  Relationships between prostate-specific antigen and prostate volume in black and white men with benign prostate biopsies.

Authors:  J E Fowler; S A Bigler; N K Kilambi; S A Land
Journal:  Urology       Date:  1999-06       Impact factor: 2.649

4.  Effects of obesity and height on prostate-specific antigen (PSA) and percentage of free PSA levels among African-American and Caucasian men.

Authors:  Jay H Fowke; Lisa B Signorello; Sam S Chang; Charles E Matthews; Maciej S Buchowski; Michael S Cookson; Flora M Ukoli; William J Blot
Journal:  Cancer       Date:  2006-11-15       Impact factor: 6.860

5.  An assessment of the comprehension of the American Urological Association Symptom Index.

Authors:  S A MacDiarmid; T C Goodson; T M Holmes; P R Martin; R B Doyle
Journal:  J Urol       Date:  1998-03       Impact factor: 7.450

6.  Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.

Authors:  Alan R Kristal; Kathryn B Arnold; Jeannette M Schenk; Marian L Neuhouser; Noel Weiss; Phyllis Goodman; Colleen M Antvelink; David F Penson; Ian M Thompson
Journal:  J Urol       Date:  2007-04       Impact factor: 7.450

7.  Knowledge, attitudes and beliefs of women about the importance of prostate cancer screening.

Authors:  Kristi Blanchard; Tracy Proverbs-Singh; Adrienne Katner; Deborah Lifsey; Steven Pollard; Walter Rayford
Journal:  J Natl Med Assoc       Date:  2005-10       Impact factor: 1.798

8.  Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey.

Authors:  Varant Kupelian; John T Wei; Michael P O'Leary; John W Kusek; Heather J Litman; Carol L Link; John B McKinlay
Journal:  Arch Intern Med       Date:  2006-11-27

9.  Urologic diseases in America project: benign prostatic hyperplasia.

Authors:  John T Wei; Elizabeth Calhoun; Steven J Jacobsen
Journal:  J Urol       Date:  2005-04       Impact factor: 7.450

10.  Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo.

Authors:  E David Crawford; Shandra S Wilson; John D McConnell; Kevin M Slawin; Michael C Lieber; Joseph A Smith; Alan G Meehan; Oliver M Bautista; William R Noble; John W Kusek; Leroy M Nyberg; Claus G Roehrborn
Journal:  J Urol       Date:  2006-04       Impact factor: 7.450

View more
  14 in total

1.  Association between physical activity, lower urinary tract symptoms (LUTS) and prostate volume.

Authors:  Jay H Fowke; Sharon Phillips; Tatsuki Koyama; Susan Byerly; Raoul Concepcion; Saundra S Motley; Peter E Clark
Journal:  BJU Int       Date:  2012-06-22       Impact factor: 5.588

Review 2.  Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome.

Authors:  Linda Vignozzi; Mauro Gacci; Mario Maggi
Journal:  Nat Rev Urol       Date:  2016-01-12       Impact factor: 14.432

3.  Is there room for behavioral and modifiable health-related targets in the lower urinary tract symptoms' scenario.

Authors:  Osamu Ikari; Brunno C F Sanches; João Carlos Cardoso Alonso; Fabiano A Simões; Ronald F Rejowski; Walker Wendel Laranja; Leonardo O Reis
Journal:  World J Urol       Date:  2017-01-25       Impact factor: 4.226

4.  Lower urinary tract symptoms and diet quality: findings from the 2000-2001 National Health and Nutrition Examination Survey.

Authors:  Bradley A Erickson; Mary Vaughan-Sarrazin; Xin Liu; Benjamin N Breyer; Karl J Kreder; Peter Cram
Journal:  Urology       Date:  2012-06       Impact factor: 2.649

5.  Association between life-style, metabolic syndrome and lower urinary tract symptoms and its impact on quality of life in men ≥ 40 years.

Authors:  Ji Bong Jeong; Jung Hoon Lee; Min Soo Choo; Dong-Won Ahn; Su Hwan Kim; Dong Seok Lee; Min Chul Cho; Hwancheol Son; Hyeon Jeong; Sangjun Yoo
Journal:  Sci Rep       Date:  2022-04-27       Impact factor: 4.996

6.  Differential adoption of laser prostatectomy for treatment of benign prostatic hyperplasia.

Authors:  Florian R Schroeck; John M Hollingsworth; Brent K Hollenbeck; Bruce L Jacobs; Anne M Suskind; Aruna V Sarma; John T Wei
Journal:  Urology       Date:  2013-03-19       Impact factor: 2.649

7.  The effect of hypercholesterolemia on carbachol-induced contractions of the detrusor smooth muscle in rats: increased role of L-type Ca2+ channels.

Authors:  Zeynep Dicle Balkanci; Bilge Pehlivanoğlu; Sibel Bayrak; Ismail Karabulut; Serkan Karaismailoğlu; Ayşen Erdem
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-08-07       Impact factor: 3.000

8.  A prospective study of statin drug use and lower urinary tract symptoms in older men.

Authors:  Alison M Mondul; Edward Giovannucci; Elizabeth A Platz
Journal:  Am J Epidemiol       Date:  2013-07-11       Impact factor: 4.897

9.  The prevalence of lower urinary tract symptoms in a Chinese population, and the correlation with uroflowmetry and disease perception.

Authors:  Chi-Hang Yee; Joseph K M Li; Hon-Chung Lam; Eddie S Y Chan; Simon See-Ming Hou; Chi-Fai Ng
Journal:  Int Urol Nephrol       Date:  2013-10-18       Impact factor: 2.370

10.  Genetic Determinants of Metabolism and Benign Prostate Enlargement: Associations with Prostate Volume.

Authors:  Ayush Giri; Todd L Edwards; Saundra S Motley; Susan H Byerly; Jay H Fowke
Journal:  PLoS One       Date:  2015-07-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.